INS and Insulin resistance: In a double-blind, placebo-controlled RCT conducted by Frøssing et al. [54] in women with PCOS, BMI ≥ 25 kg/m2 and/or insulin resistance, treatment with liraglutide 1.8 mg/day for 26 weeks, along with a higher weight loss, induced significant reductions in fasting plasma glucose, HbA1c, and plasma glucose AUC, whereas Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Matsuda index and insulin AUC remained unchanged.